Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWHNASDAQ:ATAINYSE:MBXNASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.30+0.5%$0.34$0.27▼$1.23$61.33M1.03117,360 shs17,000 shsATAIatai Life Sciences$2.18+3.1%$1.87$1.03▼$2.64$435.74M1.481.73 million shs694,043 shsMBXMBX Biosciences$11.42+3.3%$10.87$4.81▼$27.50$380.70MN/A250,574 shs159,840 shsRNACCartesian Therapeutics$10.31-0.5%$10.44$8.46▼$29.65$266.25M0.33111,718 shs15,143 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness+1.91%+2.97%+0.20%-12.18%-68.90%ATAIatai Life Sciences+4.46%-4.95%+2.43%+43.54%+50.71%MBXMBX Biosciences+13.57%+9.41%-9.05%+42.58%+1,104,999,900.00%RNACCartesian Therapeutics+5.39%+5.82%+13.10%-30.38%-55.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAWHAscend WellnessN/AN/AN/AN/AN/AN/AN/AN/AATAIatai Life Sciences2.8811 of 5 stars3.73.00.00.02.41.70.6MBXMBX Biosciences2.7585 of 5 stars3.50.00.00.02.03.30.6RNACCartesian Therapeutics1.4266 of 5 stars3.40.00.00.01.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 4.00Strong BuyN/AN/AATAIatai Life Sciences 3.33Buy$8.67298.47% UpsideMBXMBX Biosciences 3.00Buy$37.50228.37% UpsideRNACCartesian Therapeutics 2.71Moderate Buy$41.25300.10% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, ATAI, RNAC, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ATAIatai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIatai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.004/10/2025MBXMBX BiosciencesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.004/10/2025MBXMBX BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00 ➝ $44.004/10/2025MBXMBX BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$38.004/9/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $41.004/9/2025RNACCartesian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.12$0.05 per share6.64$0.69 per share0.43ATAIatai Life Sciences$310K1,405.61N/AN/A$0.69 per share3.15MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ARNACCartesian Therapeutics$38.91M6.88N/AN/A($0.27) per share-38.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.40N/AN/AN/A-15.47%-72.18%-9.55%N/AATAIatai Life Sciences-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ARNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/A-510.72%N/A-7.01%8/6/2025 (Estimated)Latest AAWH, ATAI, RNAC, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ATAIatai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/AATAIatai Life SciencesN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80ATAIatai Life Sciences0.084.074.07MBXMBX BiosciencesN/AN/AN/ARNACCartesian TherapeuticsN/A12.3412.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.31%ATAIatai Life Sciences28.41%MBXMBX BiosciencesN/ARNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.08%ATAIatai Life Sciences26.80%MBXMBX Biosciences52.19%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableATAIatai Life Sciences80200.34 million146.65 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/ARNACCartesian Therapeutics6425.95 million10.30 millionOptionableAAWH, ATAI, RNAC, and MBX HeadlinesRecent News About These CompaniesWe're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateJune 21, 2025 | finance.yahoo.comCartesian Therapeutics holds annual stockholders meetingJune 18, 2025 | investing.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus PT from AnalystsJune 17, 2025 | americanbankingnews.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 14, 2025 | marketbeat.comCantor Fitzgerald Comments on RNAC FY2026 EarningsJune 10, 2025 | marketbeat.comNuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)June 5, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisMay 30, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust CorpMay 28, 2025 | marketbeat.comCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 13, 2025 | manilatimes.netAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comCartesian Therapeutics (RNAC) Gets a Buy from Mizuho SecuritiesMay 11, 2025 | theglobeandmail.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 11, 2025 | finance.yahoo.comCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWhy Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside PotentialMay 5, 2025 | insidermonkey.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2, 2025 | globenewswire.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%April 22, 2025 | aaii.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%April 15, 2025 | aaii.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 21.84%April 15, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAWH, ATAI, RNAC, and MBX Company DescriptionsAscend Wellness OTC:AAWH$0.30 +0.00 (+0.47%) As of 10:34 AM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.atai Life Sciences NASDAQ:ATAI$2.17 +0.07 (+3.08%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.MBX Biosciences NYSE:MBX$11.42 +0.37 (+3.35%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Cartesian Therapeutics NASDAQ:RNAC$10.31 -0.05 (-0.48%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
